Bolt Biotherapeutics, Inc. (BOLT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.1500 |
| Open | 2.1400 |
| Bid | 1.9800 x 3100 |
| Ask | 2.0600 x 1200 |
| Day's Range | 1.9300 - 2.1521 |
| 52 Week Range | 1.3900 - 19.2850 |
| Volume | |
| Avg. Volume | 309,477 |
| Market Cap | 75.693M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6360 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.80 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BOLT
Related Research
- Bolt Biotherapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 02/12/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- Zacks
Zacks.com featured highlights include Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery
Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery are part of screen of the week article.
- GlobeNewswire
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it will be presenting a poster at the 2022 American Society of Clinical O
- Simply Wall St.
The past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitable
Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply accept every...
